These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18845330)

  • 1. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy.
    Müller UR; Jutel M; Reimers A; Zumkehr J; Huber C; Kriegel C; Steiner U; Haeberli G; Akdis M; Helbling A; Schnyder B; Blaser K; Akdis C
    J Allergy Clin Immunol; 2008 Nov; 122(5):1001-1007.e4. PubMed ID: 18845330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy.
    Müller U; Hari Y; Berchtold E
    J Allergy Clin Immunol; 2001 Jan; 107(1):81-6. PubMed ID: 11149995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.
    Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B
    Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication with antihistamines impairs allergen-specific immunotherapy in mice.
    Johansen P; Senti G; Maria Martínez Gómez J; Kündig TM
    Clin Exp Allergy; 2008 Mar; 38(3):512-9. PubMed ID: 18081882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial.
    Severino MG; Cortellini G; Bonadonna P; Francescato E; Panzini I; Macchia D; Campi P; Spadolini I; Canonica WG; Passalacqua G
    J Allergy Clin Immunol; 2008 Jul; 122(1):44-8. PubMed ID: 18468672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.
    Jutel M; Pichler WJ; Skrbic D; Urwyler A; Dahinden C; Müller UR
    J Immunol; 1995 Apr; 154(8):4187-94. PubMed ID: 7706753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract.
    Enrique E; Pineda F; Malek T; Bartra J; Basagaña M; Tella R; Castelló JV; Alonso R; de Mateo JA; Cerdá-Trias T; San Miguel-Moncín Mdel M; Monzón S; García M; Palacios R; Cisteró-Bahíma A
    J Allergy Clin Immunol; 2005 Nov; 116(5):1073-9. PubMed ID: 16275379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study].
    Silny W; Czarnecka-Operacz M
    Pol Merkur Lekarski; 2006 Dec; 21(126):558-65. PubMed ID: 17405298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the diagnosis and treatment of hymenoptera venom allergy.
    Müller UR
    Int Arch Allergy Immunol; 2001 Apr; 124(4):447-53. PubMed ID: 11340327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
    Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
    J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.
    Müller U; Akdis CA; Fricker M; Akdis M; Blesken T; Bettens F; Blaser K
    J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):747-54. PubMed ID: 9648701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.
    Winther L; Arnved J; Malling HJ; Nolte H; Mosbech H
    Clin Exp Allergy; 2006 Mar; 36(3):254-60. PubMed ID: 16499635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic response to administration of standardized dog allergen extract at differing doses.
    Lent AM; Harbeck R; Strand M; Sills M; Schmidt K; Efaw B; Lebo T; Nelson HS
    J Allergy Clin Immunol; 2006 Dec; 118(6):1249-56. PubMed ID: 17157654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled, crossover trial.
    Brown SG; Haas MA; Black JA; Parameswaran A; Woods GM; Heddle RJ
    Clin Exp Allergy; 2004 May; 34(5):792-800. PubMed ID: 15144473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety.
    Tabar AI; Lizaso MT; García BE; Gómez B; Echechipía S; Aldunate MT; Madariaga B; Martínez A
    Pediatr Allergy Immunol; 2008 Feb; 19(1):67-75. PubMed ID: 17651380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.
    Korošec P; Žiberna K; Šilar M; Dežman M; Čelesnik Smodiš N; Rijavec M; Kopač P; Eržen R; Lalek N; Bajrović N; Košnik M; Zidarn M
    Clin Exp Allergy; 2015 Oct; 45(10):1579-89. PubMed ID: 26046807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
    Launay O; Roudière L; Boukli N; Dupont B; Prévoteau du Clary F; Patey O; David F; Lortholary O; Devidas A; Piketty C; Rey E; Urbinelli R; Allaert FA; Tréluyer JM; Caumes E;
    Clin Infect Dis; 2004 Apr; 38(8):e66-72. PubMed ID: 15095233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.